CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
原发性中枢神经系统淋巴瘤免疫治疗的新兴格局
英文原题：Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma.
查看英文原题
Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
原发性中枢神经系统淋巴瘤（PCNSL）主要为非生发中心B细胞来源的弥漫性大B细胞淋巴瘤（DLBCL），预后较差，且存在显著未满足的医疗需求。免疫疗法已成为最有前景的研究领域之一，并已纳入多种实体瘤和血液系统肿瘤的标准治疗。对于复发/难治性PCNSL，这类新疗法引发了极大关注。本文讨论PCNSL免疫治疗面临的挑战，包括淋巴瘤细胞本身以及特殊的脑部免疫微环境；综述当前临床开发进展，涵盖抗CD20单克隆抗体、CAR-T 细胞、免疫检查点抑制剂，以及可对脑部微环境产生瘤外作用的靶向治疗；并提出提高免疫疗法疗效、优化其在PCNSL中治疗作用的展望。
展开英文摘要原文
Primary central nervous system lymphoma (PCNSL) is, mainly, a diffuse large B-cell lymphoma (DLBCL) with a non-germinal center B-cell (non-GCB) origin. It is associated with a poor prognosis and an unmet medical need. Immunotherapy has emerged as one of the most promising areas of research and is now part of the standard treatment for many solid and hematologic tumors. This new class of therapy generated great enthusiasm for the treatment of relapsed/refractory PCNSL.
Here, we discuss the challenges of immunotherapy for PCNSL represented by the lymphoma cell itself and the specific immune brain microenvironment.
We review the current clinical development from the anti-CD20 monoclonal antibody to CAR-T cells, as well as immune checkpoint inhibitors and targeted therapies with off-tumor effects on the brain microenvironment. Perspectives for improving the efficacy of immunotherapies and optimizing their therapeutic role in PCNSL are suggested.
论文信息
- 作者
- Alcantara M、Fuentealba J、Soussain C
- 单位
- Center for Cancer Immunotherapy, Institut Curie, PSL Research University, INSERM U932, 75005 Paris, France.France
- 文献类型
- 综述
- 期刊
- Cancers2021 Oct 10
- 原文标识
- PubMed 34680209 · DOI 10.3390/cancers13205061
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →